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A risky business
In a world full of seemingly intractable problems, health-
related and otherwise, knowing where to start or what to 
prioritise can be daunting. One of the principles by which 
to allocate scarce medical resources is to focus on the 
worst oﬀ —ie, the sickest. In a prevention context, this 
might translate to the most at risk. The diverse research 
articles in this month’s issue follow this philosophy.
In their analysis of Demographic and Health Surveys 
from 54 low-income and middle-income countries, 
Rishi Caleyachetty and colleagues estimate the prevalence 
of tobacco use (both smoked and smokeless) in pregnant 
women. These individuals are doubly at risk. First, their 
status as pregnant clearly puts them in a category where 
harm is at its maximal. The damage caused by maternal 
tobacco use in terms of pregnancy complications, 
stillbirth, prematurity, low birthweight, and sudden infant 
death syndrome hardly needs repeating. But women 
of childbearing age in low-income and middle-income 
countries, pregnant or not, are also at risk because—as a 
potential “growth market”—they are ﬁ rmly in the cross-
hairs of Big Tobacco. Caleyachetty and colleagues’ ﬁ nding 
of a low overall prevalence of tobacco use in pregnant 
women from these countries (around 2·6%) should be 
taken as a baseline from which to work hard to improve, 
and not a reassuring conﬁ rmation of a non-issue.
High-risk groups were the target of the south Indian HIV 
prevention programme, Avahan. Implemented across six 
states between 2004 and 2008, the intervention involved 
services such as peer-led outreach, education, and condom 
distribution; free treatment of sexually transmitted 
infections (STIs); and free supplies of condoms and STI 
drugs. The aim was to prevent HIV infection among female 
sex workers and their clients, men who have sex with men, 
and injecting drug users. A previous study in this journal 
demonstrated the population-level eﬀ ectiveness of the 
programme; Anna Vassall and colleagues now reveal that 
it was also good value for money. The researchers estimate 
a mean incremental cost per disability-adjusted life-year 
averted of $46. As Elliot Marseille and James Kahn state 
in their accompanying Comment, this ﬁ gure is “roughly 
on par with the provision of insecticide-treated bednets 
to prevent malaria; diarrhoeal disease prevention with 
the promotion of hygiene practices; volunteer paramedic 
training in emergency care; and the provision of childhood 
immunisation against tuberculosis, diphtheria, polio, 
and measles”. It is a welcome aﬃ  rmation of the cost-
eﬀ ectiveness of targeted population prevention of HIV.
Finally, to an unwitting group at high risk of trans-
mitting hepatitis C virus (HCV). Egypt has the highest 
prevalence of HCV infection in the world. 15% of people 
aged 15–59 years are estimated to be infected, mainly as 
a result of contaminated medical equipment used to give 
mass treatment for schistosomiasis in the 1960–80s. The 
current transmission status is unknown, as is whether the 
present national control strategy is likely to be eﬀ ective. 
A modelling study by Romulus Breban and colleagues 
indicates that, without treatment, the HCV epidemic in 
Egypt is self-sustaining—ie, transmission would continue 
even after all those originally infected died. The drivers 
of this sustained transmission, the model suggests, are 
individuals who undergo more than the mean number of 
medical injections per year and who pass on the virus via 
suboptimal safety practices within health-care facilities. 
Simulations indicate that the present screening and 
subsidised treatment strategy, which only covers Ministry 
of Health and Population facilities (and thus only 30% of 
the population), will not interrupt transmission. What is 
likely to be most eﬀ ective is a strategy that targets the 
high-risk group of multiple injectors within 2·5 years of 
chronic infection. Will the Egyptian Government take 
heed? Breban speculates about this in a linked podcast.
Being aware of what puts us at risk is a basic pre-
requisite of any programme to help us mitigate those 
risks. But what if we don’t trust the people who are 
identifying them? What if we suspect them of being 
part of the problem? Consider the situation in west 
Africa where a terrible breakdown in trust seems to be 
thwarting eﬀ orts to contain the spread of Ebola. In his 
blog post, Francis Omaswa, who led Uganda’s response 
to the previously largest outbreak, outlines his recipe 
for regaining trust. He recommends harnessing the 
media via regular in-person press conferences, and 
recruiting community leaders in control eﬀ orts. That 
communication and societal involvement is key to 
risk reduction is hardly revelatory. But when medical 
resources are scarce, or a crisis emerges, they can be 
forgotten weapons in the armamentarium.
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